drugset / Trial / NCT05595993

Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache

NCT05595993

Unknown 21 enrolled Danish Headache Center
RandomizedCrossoverQuadruple-blindBasic science

Summary

To investigate whether cilostazol (phosphodiesterase 3 inhibitor) induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

Timeline

Start
2022-10-25
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilostazol Small molecule 200 mg Oral

Indications

No indication recorded.